Biomarkers and patient-related factors associated with clinical outcomes in dupilumab-treated atopic dermatitis
Makiko Kido-Nakahara,Daisuke Onozuka,Kenji Izuhara,Hidehisa Saeki,Satoshi Nunomura,Motoi Takenaka,Mai Matsumoto,Yoko Kataoka,Rai Fujimoto,Sakae Kaneko,Eishin Morita,Akio Tanaka,Michihiro Hide,Tatsuro Okano,Tomomitsu Miyagaki,Natsuko Aoki,Kimiko Nakajima,Susumu Ichiyama,Kyoko Tonomura,Yukinobu Nakagawa,Risa Tamagawa-Mineoka,Koji Masuda,Takuya Takeichi,Masashi Akiyama,Yozo Ishiuji,Michie Katsuta,Yuki Kinoshita,Chiharu Tateishi,Aya Yamamoto,Akimichi Morita,Haruna Matsuda-Hirose,Yutaka Hatano,Hiroshi Kawasaki,Keiji Tanese,Mamitaro Ohtsuki,Koji Kamiya,Yudai Kabata,Riichiro Abe,Hiroshi Mitsui,Tatsuyoshi Kawamura,Gaku Tsuji,Masutaka Furue,Norito Katoh,Takeshi Nakahara
DOI: https://doi.org/10.1016/j.jacig.2024.100317
2024-07-31
Abstract:Background: Atopic dermatitis (AD) is a common chronic eczematous skin disease with severe pruritus. Several new therapeutic agents for AD such as dupilumab, an anti-IL-4Rα antibody, have been developed in recent years. We need to predict which agent is the best choice for each patient, but this remains difficult. Objective: Our aim was to examine clinical background factors and baseline biomarkers that could predict the achievement of improved clinical outcomes in patients with AD treated with dupilumab. Methods: A multicenter, prospective observational study was conducted on 110 patients with AD. The Eczema Area and Severity Index was used as an objective assessment, and the Patient-Oriented Eczema Measure and Numerical Rating Scale for Pruritus were used as patient-reported outcomes. In addition, some clinical background factors were evaluated. Results: The achievement of an absolute Eczema Area and Severity Index of 7 or less was negatively associated with current comorbidity of food allergy and baseline serum lactate dehydrogenase (LDH) levels. There were negative associations between achievement of a Patient-Oriented Eczema Measure score of 7 or less and duration of severe AD and between achievement of an itching Numerical Rating Scale for Pruritus score of 1 or less and current comorbidity of allergic conjunctivitis or baseline serum periostin level. Furthermore, signal detection analysis showed that a baseline serum LDH level less than 328 U/L could potentially be used as a cutoff value for predicting the efficacy of dupilumab. Conclusion: Baseline biomarkers such as LDH and periostin and clinical background factors such as current comorbidity of food allergy and a long period of severe disease may be useful indicators when choosing dupilumab for systemic treatment for AD, as they can predict the efficacy of dupilumab.